Nampalli Vijay
Cardiovascular Disease · Denver, CONPI 1548256936
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Amgen at 46.3% of the total. Reporting peaked in 2021 at $1,869 and has fallen 96.0% since, to $75 in 2025.
Across 98 payments — averaging $45.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Janssen Research & Development, LLC$1K
- Pfizer$190
- Sanofi-aventis U.S. LLC$177
- AstraZeneca$101
- Boston Scientific$97
- plus $708 from 17 others
Across 76 payments — averaging $9328.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$384K
- Novartis$271K
- Janssen Research & Development, LLC$24K
- CSL Behring$18K
- United Therapeutics Corporation$9K
- Eli Lilly$3K
What the payments were for
- Consulting fees$421%
- Speaking & faculty fees$1,81441%
- Travel & lodging$80518%
- Food & beverage$1,74440%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 11 | $2,045 |
| Janssen Research & Development, LLC | 10 | $1,095 |
| Pfizer | 13 | $190 |
| Sanofi-aventis U.S. LLC | 10 | $177 |
| AstraZeneca | 6 | $101 |
| Boston Scientific | 3 | $97 |
| Boehringer Ingelheim | 7 | $96 |
| Johnson & Johnson | 5 | $75 |
| Novartis | 4 | $73 |
| United Therapeutics Corporation | 4 | $58 |
| Astellas Pharma US Inc | 3 | $51 |
| Akcea Therapeutics, Inc. | 3 | $45 |
| Regeneron Healthcare Solutions, Inc. | 3 | $43 |
| Biotronik Inc. | 2 | $38 |
| Medtronic | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $32 |
| Amarin Pharma, Inc. | 2 | $28 |
| Abbott | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$1,814
How this compares
$4,412 in reported general payments places this provider in the 70th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Denver
- Andrew FreemanDenver$454K
- Sameer MehtaDenver$92K
- Jake ChaninDenver$82K
- John RumsfeldDenver$24K
- Mori KrantzDenver$22K
- Fady IskanderDenver$16K
- Jose SanchezDenver$8K
- Sam RougasDenver$6K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.